GILEAD SCIENCES, INC. is 82.1x more valuable than NOVAVAX INC by market capitalization ($151.05 B vs $1.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NVAX | GILD |
|---|---|---|
| Market cap | $1.84 B | $151.05 B |
| US-listed rank | #2165 | #99 |
| Revenue (latest FY) | $1.12B | $29.44B |
| Net income (latest FY) | $440.30M | $8.51B |
| Net margin | 39.2% | 28.9% |
| P/E (trailing FY) | 4.2 | 17.7 |
| SEC filings | 1,627 | 981 |
GILEAD SCIENCES, INC. is 82.1x more valuable than NOVAVAX INC by market capitalization ($151.05 B vs $1.84 B).
In their latest fiscal years, NOVAVAX INC reported $1.12B in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: NOVAVAX INC and GILEAD SCIENCES, INC., or browse the full rankings.